Learn More
CD272 (BTLA) Mouse anti-Human, Brilliant Violet 605, Clone: J168-540, BD Optibuild™
Description
The J168-540 monoclonal antibody specifically binds to human CD272, also known as BTLA (B and T lymphocyte attenuator), an inhibitory receptor expressed in bone marrow and thymus on developing B and T cells. In the periphery, BTLA is expressed by B cells, T cells, bone marrow-derived dendritic cells, and macrophages. After T cell activation, BTLA appears to be expressed at higher levels on Th1 cell populations than in Th2 cell populations. Upon binding the herpesvirus entry mediator (HVEM/LIGHT-R/CD270), CD272 undergoes tyrosine phosphorylation and inhibits T cell proliferation in a BTLA-dependent manner. CD272 has structural similarities to two other lymphocyte inhibitory receptors, CTLA-4 and PD-1 and is a member of the CD28-like family of coreceptors. Based on these observations, CD272 is considered to be a negative regulator of lymphocyte activation and/or function.
Specifications
Specifications
| Antígeno | CD272 (BTLA) |
| Clasificación | Monoclonal |
| Clon | J168-540 |
| Concentración | 0.2mg/mL |
| Conjugado | Brilliant Violet 605 |
| Formulación | Aqueous buffered solution containing ≤0.09% sodium azide. |
| Alias de gen | BTLA1, B- and T-lymphocyte-associated protein |
| Especie del huésped | Mouse |
| Inmunógeno | Human BTLA Recombinant Protein |
| Método de purificación | Affinity Purified |
| Show More |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.